AU2004279441B2 - Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia - Google Patents
Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia Download PDFInfo
- Publication number
- AU2004279441B2 AU2004279441B2 AU2004279441A AU2004279441A AU2004279441B2 AU 2004279441 B2 AU2004279441 B2 AU 2004279441B2 AU 2004279441 A AU2004279441 A AU 2004279441A AU 2004279441 A AU2004279441 A AU 2004279441A AU 2004279441 B2 AU2004279441 B2 AU 2004279441B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- cll
- chain antibody
- gene
- antibody gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50947303P | 2003-10-08 | 2003-10-08 | |
| US60/509,473 | 2003-10-08 | ||
| PCT/US2004/033176 WO2005034733A2 (en) | 2003-10-08 | 2004-10-08 | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004279441A1 AU2004279441A1 (en) | 2005-04-21 |
| AU2004279441B2 true AU2004279441B2 (en) | 2010-07-01 |
Family
ID=34434984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004279441A Ceased AU2004279441B2 (en) | 2003-10-08 | 2004-10-08 | Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8119340B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1678195A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007510622A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004279441B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2541360A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005034733A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2541360A1 (en) | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| US20070105165A1 (en) * | 2005-11-04 | 2007-05-10 | Charles Goolsby | Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers |
| US7767206B2 (en) * | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
| NZ604007A (en) | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
| EP3957653A1 (en) * | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| DE102012212025A1 (de) * | 2012-07-10 | 2014-01-16 | Osram Gmbh | Leuchtmodul |
| EP2741084B1 (en) | 2012-12-07 | 2020-01-22 | AVA Lifescience GmbH | Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL) |
| JP2016507520A (ja) | 2013-01-23 | 2016-03-10 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 安定化されたb型肝炎コアポリペプチド |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| US9976146B2 (en) * | 2014-05-30 | 2018-05-22 | Academia Sinica | Aptamer targeting MAGE-A3 peptide and uses thereof |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| WO2017023859A1 (en) * | 2015-07-31 | 2017-02-09 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting cd56 and uses thereof |
| US20170073397A1 (en) * | 2015-08-24 | 2017-03-16 | Medimmune, Llc | MrkA Polypeptides, Antibodies, and Uses Thereof |
| AU2016319126A1 (en) | 2015-09-10 | 2018-04-19 | Affigen, Inc. | Sequencing-directed selection of tumor theranostics |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| US10836810B2 (en) | 2017-02-17 | 2020-11-17 | Mapp Biopharmaceutical, Inc. | Monoclonal antibodies and cocktails for treatment of ebola infections |
| WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル-マイヤーズ スクイブ カンパニー | 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物 |
| CN109752548B (zh) * | 2019-02-01 | 2022-05-06 | 广州金域医学检验中心有限公司 | 评估慢性淋巴细胞白血病预后的组合试剂及系统 |
| US12378321B2 (en) | 2019-03-08 | 2025-08-05 | Memorial Sloan Kettering Cancer Center | ADAM17 binding molecules and uses thereof |
| EP4013794A4 (en) | 2019-08-12 | 2023-11-22 | City of Hope | ANTI-IL1RAP ANTIBODIES |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| EP4341289A1 (en) * | 2021-05-18 | 2024-03-27 | Christian-Albrechts-Universität zu Kiel | Co-stimulatory multispecific antibodies |
| CN113461818B (zh) * | 2021-06-30 | 2022-01-21 | 徐州医科大学 | 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法 |
| AU2023231622A1 (en) * | 2022-03-07 | 2024-09-26 | Agenus Inc. | Anti-ilt2 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP2270049A3 (en) * | 2002-04-12 | 2011-03-09 | Medimmune, Inc. | Recombinant anti-interleukin-9-antibody |
| CA2541360A1 (en) | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
-
2004
- 2004-10-08 CA CA002541360A patent/CA2541360A1/en not_active Abandoned
- 2004-10-08 EP EP04794503A patent/EP1678195A4/en not_active Withdrawn
- 2004-10-08 WO PCT/US2004/033176 patent/WO2005034733A2/en not_active Ceased
- 2004-10-08 JP JP2006534362A patent/JP2007510622A/ja active Pending
- 2004-10-08 AU AU2004279441A patent/AU2004279441B2/en not_active Ceased
- 2004-10-08 US US10/575,671 patent/US8119340B2/en active Active
-
2012
- 2012-01-20 US US13/354,774 patent/US9745364B2/en not_active Expired - Fee Related
Non-Patent Citations (6)
| Title |
|---|
| CARTER, P., Nat. Rev. Cancer. 2001, vol. 1, no. 2, pages 118-129 (Y) * |
| CHIORAZZI, N. et al., Annual Review of Immunology, April 2003, vol. 21, pages 841-894 (Y) * |
| CHIORAZZI, N. et al., In Chronic lymphoid leukemia, 2nd Ed. B.D. Cheson, editor Marcel Dekker, New York. 2001, pages 81-109 (Y) * |
| DAMLE et al., Blood. 1999, Vo1.94, pages 1840-1847 (Y) * |
| FAIS et al., J. Clin. Invest. 1998, Vol. 102, pages 1515-1525 (Y) * |
| VALETTO, A . et al., Blood, 1998, vol. 92, no. 10 SUPPL. 1, PART 1-2, page 431A (Y) * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005034733A2 (en) | 2005-04-21 |
| US20120141462A1 (en) | 2012-06-07 |
| AU2004279441A1 (en) | 2005-04-21 |
| JP2007510622A (ja) | 2007-04-26 |
| EP1678195A2 (en) | 2006-07-12 |
| US20090117095A1 (en) | 2009-05-07 |
| EP1678195A4 (en) | 2008-04-23 |
| WO2005034733A3 (en) | 2005-09-09 |
| CA2541360A1 (en) | 2005-04-21 |
| US9745364B2 (en) | 2017-08-29 |
| US8119340B2 (en) | 2012-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9745364B2 (en) | Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia | |
| Messmer et al. | Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia | |
| Marasca et al. | Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma | |
| Hardy et al. | A single VH gene is utilized predominantly in anti-BrMRBC hybridomas derived from purified Ly-1 B cells. Definition of the VH11 family. | |
| Craig et al. | Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins | |
| CN101668853B (zh) | 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用 | |
| Bos et al. | Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria | |
| EP3722314A1 (en) | Anti-vista antibodies and fragments | |
| CA2445989A1 (en) | Colon cancer antigen panel | |
| JPH07503062A (ja) | 慢性関節リューマチの診断と治療用のVα12.1T細胞リセプターに特異的な試薬 | |
| Ghosh et al. | In situ diversification of the antibody repertoire in chronic Lyme arthritis synovium | |
| Feeney et al. | Human cord blood kappa repertoire | |
| US8722350B2 (en) | Methods and compositions for categorizing patients | |
| JP2008527998A (ja) | Nsclcの診断のためのgitr抗体 | |
| US7118912B2 (en) | Methods and compositions for categorizing patients | |
| Roers et al. | Single-cell PCR analysis of T helper cells in human lymph node germinal centers | |
| Diaw et al. | Double producers of kappa and lambda define a subset of B cells in mouse plasmacytomas | |
| Dyer et al. | Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias | |
| Smilevska et al. | Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma | |
| Bende et al. | Immunoglobulin diversification in B cell malignancies: internal splicing of heavy chain variable region as a by-product of somatic hypermutation | |
| US20050181370A1 (en) | Cancer-associated nucleic acids and polypeptides | |
| Li et al. | Repertoire diversification in mice with an IgH-locus-targeted transgene for the rearranged VH domain of a physiologically selected anti-ssDNA antibody | |
| US20050233353A1 (en) | Methods and compositions for categorizing patients | |
| EP4514952A1 (en) | Terminal deoxynucleotidyl transferase antibodies and uses thereof | |
| Neubauer et al. | Gastric MALT lymphoma B cells express polyreactive, somatically mutated |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH Free format text: FORMER NAME: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |